Ascendis Pharma A (ASND) Enterprise Value (2012 - 2026)

Ascendis Pharma A has disclosed Enterprise Value across 15 years of filings, most recently posting -$670.6 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$670.6 million, down 23.1% year-over-year; the trailing twelve-month figure through Mar 2026 was -$670.6 million (down 23.1% YoY), and the FY2025 annual result was -$717.1 million, down 19.93% from the prior year.
• Enterprise Value came in at -$670.6 million for Q1 2026 at Ascendis Pharma A, up from -$717.1 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$278.6 million in Q2 2024 to a low of -$849.4 million in Q1 2022.
• The 5-year median for Enterprise Value is -$559.2 million (2025), against an average of -$562.9 million.
• Across the five-year window, Enterprise Value surged 40.36% in 2023 and tumbled 100.74% in 2025, its largest moves.
• Ascendis Pharma A's Enterprise Value stood at -$471.1 million in 2022, then increased by 8.77% to -$429.8 million in 2023, then sank by 39.13% to -$597.9 million in 2024, then retreated by 19.93% to -$717.1 million in 2025, then increased by 6.48% to -$670.6 million in 2026.
• The last three Enterprise Value figures came in at -$670.6 million (Q1 2026), -$717.1 million (Q4 2025), and -$630.2 million (Q3 2025), per Business Quant data.